HIV Anti-retroviral Background Therapy — Competitive Intelligence Brief

HIV Anti-retroviral Background Therapy (HIV Anti-retroviral Background Therapy) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: CCR5 antagonist. Area: Infectious Disease.

phase 2 CCR5 antagonist CCR5 Infectious Disease Small molecule

Target snapshot

HIV Anti-retroviral Background Therapy (HIV Anti-retroviral Background Therapy) — Theratechnologies. Inhibits HIV replication by targeting the CCR5 receptor

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
HIV Anti-retroviral Background Therapy TARGET	HIV Anti-retroviral Background Therapy	Theratechnologies	phase 2	CCR5 antagonist	CCR5
Sirolimus + Maraviroc	Sirolimus + Maraviroc	University of Maryland, Baltimore	marketed	mTOR inhibitor + CCR5 antagonist combination	mTOR; CCR5
Standard-of-care Antiretroviral therapy	Standard-of-care Antiretroviral therapy	Medical Research Council	marketed	Antiretroviral combination therapy (multiple classes: NRTI, NNRTI, PI, INSTI, entry inhibitors)	HIV reverse transcriptase, HIV protease, HIV integrase, HIV envelope glycoproteins (CCR5/CXCR4 co-receptors)
emtricitabine, darunavir/cobicistat, maraviroc	emtricitabine, darunavir/cobicistat, maraviroc	Giovanni Di Perri	marketed	Antiretroviral combination (NRTI + PI + pharmacokinetic booster + CCR5 antagonist)	HIV reverse transcriptase, HIV protease, CYP3A4, CCR5 co-receptor
Biktarvy Tab	Biktarvy Tab	Southampton Healthcare, Inc.	marketed	Antiretroviral combination therapy (integrase inhibitor + nucleoside/nucleotide reverse transcriptase inhibitors)	HIV integrase, HIV reverse transcriptase, CCR5 co-receptor
Antiretroviral therapy	Antiretroviral therapy	ANRS, Emerging Infectious Diseases	marketed	Combination antiretroviral therapy (multiple classes: nucleoside/nucleotide reverse transcriptase inhibitors, non-nucleoside reverse transcriptase inhibitors, protease inhibitors, integrase strand transfer inhibitors, entry inhibitors)	HIV reverse transcriptase, HIV integrase, HIV protease, HIV envelope glycoproteins (gp120/gp41), CCR5 co-receptor
Antiretroviral/Anti HIV	Antiretroviral/Anti HIV	MSD Pharmaceuticals LLC	marketed	Antiretroviral agent (multiple classes: NRTI, NNRTI, PI, INSTI, entry inhibitor)	HIV reverse transcriptase, HIV protease, HIV integrase, CCR5, or CXCR4 (depending on specific agent)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (CCR5 antagonist class)

1. ANRS, Emerging Infectious Diseases · 1 drug in this class
2. Centre Hospitalier Intercommunal de Toulon La Seyne sur Mer · 1 drug in this class
3. National Institute of Allergy and Infectious Diseases (NIAID) · 1 drug in this class
4. Theratechnologies · 1 drug in this class